Company: IPSC
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001104659-25-037419
Chunk: 5

Company: Century Therapeutics, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 5
---
 ​ | ​ |
| ​ | ​ | Size of Board (set by the Board)                                   | ​ | ​ |         8 | ​ | ​ |
| ​ | ​ | Number of Independent Directors                                    | ​ | ​ |         7 | ​ | ​ |
| ​ | ​ | Independent Chairman of the Board                                  | ​ | ​ |       Yes | ​ | ​ |
| ​ | ​ | Board Self-Evaluation                                              | ​ | ​ |    Annual | ​ | ​ |
| ​ | ​ | Review of Independence of Board                                    | ​ | ​ |    Annual | ​ | ​ |
| ​ | ​ | Independent Directors Meet Without Management Present              | ​ | ​ |       Yes | ​ | ​ |
| ​ | ​ | Voting Standard for Election of Directors in Uncontested Elections | ​ | ​ | Plurality | ​ | ​ |
| ​ | ​ | Diversity of Board background, experience and skills               | ​ | ​ |       Yes | ​ | ​ |

RECENT CORPORATE HIGHLIGHTS • In March 2025, we announced that (i) the first patient in our CALiPSO-1 Phase 1 clinical trial in autoimmune diseases is enrolled and was dosed in March 2025; (ii) five sites in the U.S. are actively screening patients and (iii) we are expanding the CALiPSO-1 clinical trial to include additional sites in select European countries and expect enrollment at those sites will initiate in the second half of 2025. • In March 2025, we announced our preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies. • In March 2025, we announced early discontinuation of ELiPSE-1 program in late-stage relapsed-refractory non-Hodgkin’s lymphoma, or R/R NHL. While we remain encouraged by the clinical activity and tolerability profile of CNTY-101 in late-stage R/R NHL, the emerging clinical data do not meet our threshold to be considered transformational in this patient population and the program is being discontinued. • In March 2025, we announced that we estimate our cash, cash equivalents, and investments will support our operations into the fourth quarter of 2026. • In January 2025, we announced that we had entered into an agreement for an investigator-initiated Phase 1/2 CARAMEL clinical trial by